153 related articles for article (PubMed ID: 35932965)
21. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
22. [Co-amorphous technology to improve dissolution and physical stability of silybin].
Liu H; Zhao GW; Jiang QY; Liang XL; Ouyang LQ; Ding HB; Chen XL; Liao ZG
Zhongguo Zhong Yao Za Zhi; 2022 Jan; 47(1):103-110. PubMed ID: 35178916
[TBL] [Abstract][Full Text] [Related]
23. Surfactant-free solid dispersion of BCS class IV drug in an amorphous chitosan oligosaccharide matrix for concomitant dissolution in vitro - permeability increase.
Huang R; Han J; Wang R; Zhao X; Qiao H; Chen L; Li W; Di L; Zhang W; Li J
Eur J Pharm Sci; 2019 Mar; 130():147-155. PubMed ID: 30699368
[TBL] [Abstract][Full Text] [Related]
24. Amino acids as stabilizers for spray-dried simvastatin powder for inhalation.
Lu W; Rades T; Rantanen J; Chan HK; Yang M
Int J Pharm; 2019 Dec; 572():118724. PubMed ID: 31678523
[TBL] [Abstract][Full Text] [Related]
25. Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.
Heng W; Su M; Cheng H; Shen P; Liang S; Zhang L; Wei Y; Gao Y; Zhang J; Qian S
Mol Pharm; 2020 Jan; 17(1):84-97. PubMed ID: 31794225
[TBL] [Abstract][Full Text] [Related]
26. Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations.
Ambike AA; Mahadik KR; Paradkar A
Pharm Res; 2005 Jun; 22(6):990-8. PubMed ID: 15948043
[TBL] [Abstract][Full Text] [Related]
27. Structural, thermal, vibrational, solubility and DFT studies of a tolbutamide co-amorphous drug delivery system for treatment of diabetes.
R Sá M; Sarraguça JMG; de Sousa FF; Sarraguça MSC; Lopes JA; Lima ADDSG; Lage MR; Ribeiro PRS
Int J Pharm; 2022 Mar; 615():121500. PubMed ID: 35077862
[TBL] [Abstract][Full Text] [Related]
28. Improved Dissolution Properties of Co-amorphous Probucol with Atorvastatin Calcium Trihydrate Prepared by Spray-Drying.
Oyama S; Ogawa N; Kawai K; Iwai K; Yasunaga T; Yamamoto H
Chem Pharm Bull (Tokyo); 2024; 72(2):190-199. PubMed ID: 38369345
[TBL] [Abstract][Full Text] [Related]
29. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
[TBL] [Abstract][Full Text] [Related]
30. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
31. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
32. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation.
Jiang T; Han N; Zhao B; Xie Y; Wang S
Drug Dev Ind Pharm; 2012 Oct; 38(10):1230-9. PubMed ID: 22229827
[TBL] [Abstract][Full Text] [Related]
33. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
34. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
35. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
36. In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids.
Maher EM; Ali AM; Salem HF; Abdelrahman AA
Drug Deliv; 2016 Oct; 23(8):3088-3100. PubMed ID: 26960680
[TBL] [Abstract][Full Text] [Related]
37. Co-amorphous Systems of Sinomenine with Platensimycin or Sulfasalazine: Physical Stability and Excipient-Adjusted Release Behavior.
Chen X; Li D; Zhang H; Duan Y; Huang Y
Mol Pharm; 2022 Nov; 19(11):4370-4381. PubMed ID: 36251509
[TBL] [Abstract][Full Text] [Related]
38. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
Fael H; Demirel AL
Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
[TBL] [Abstract][Full Text] [Related]
39. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin.
Dengale SJ; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Biopharm; 2015 Jan; 89():329-38. PubMed ID: 25542681
[TBL] [Abstract][Full Text] [Related]
40. Encapsulation of (-)-epigallocatechin gallate into liposomes and into alginate or chitosan microparticles reinforced with liposomes.
Istenič K; Cerc Korošec R; Poklar Ulrih N
J Sci Food Agric; 2016 Oct; 96(13):4623-32. PubMed ID: 26921243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
